Why the study?
Chronic heart failure prevalence is steadily increasing and its pathogenesis is closely linked to metabolic syndrome, which is present in 60% of patients.
Key points are not available for this paper at this time.
Design
Review article
May support addressing metabolic syndrome in HF care; leaves open need for prospective trials to confirm progression benefit.
In recent decades, there has been a steady increase in the prevalence of chronic heart failure worldwide, which is estimated to affect up to 2% of the adult population and up to 10% of the elderly. The pathogenesis of chronic heart failure is closely linked to metabolic syndrome. Metabolic syndrome is observed in 60% of patients with chronic heart failure. The most common and potent risk factors for chronic heart failure are the components of metabolic syndrome such as visceral obesity, hyperinsulinemia, insulin resistance, dyslipidemia, hypertension and type 2 diabetes. Adequate treatment of the main components of metabolic syndrome with lifestyle adjustments and modern drug therapy can inhibit the development and progression of chronic heart failure. This article summarizes the common pathogenetic mechanisms of metabolic syndrome and chronic heart failure, as well as current opportunities for their correction.
No takes yet. Share an insight, caveat, or question.
Zhuravlyova et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: